메뉴 건너뛰기




Volumn 39, Issue 1, 2015, Pages 41-47

Role of radiation and androgen deprivation therapy for advanced prostate cancer

(2)  Jani, Ashesh B a   Rossi, Peter J a  

a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; HUMAN; PROSTATE CANCER; TREATMENT DURATION; MALE; MULTIMODALITY CANCER THERAPY; PROCEDURES; PROSTATIC NEOPLASMS;

EID: 84921789180     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2014.11.007     Document Type: Article
Times cited : (1)

References (25)
  • 1
    • 0035424063 scopus 로고    scopus 로고
    • Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate
    • Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001, 50(5):1243-1252.
    • (2001) Int J Radiat Oncol Biol Phys , vol.50 , Issue.5 , pp. 1243-1252
    • Pilepich, M.V.1    Winter, K.2    John, M.J.3
  • 2
    • 0030933348 scopus 로고    scopus 로고
    • Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer
    • Laverdiere J., Gomez J.L., Cusan L., et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997, 37(2):247-252.
    • (1997) Int J Radiat Oncol Biol Phys , vol.37 , Issue.2 , pp. 247-252
    • Laverdiere, J.1    Gomez, J.L.2    Cusan, L.3
  • 3
    • 1542267900 scopus 로고    scopus 로고
    • The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer
    • Laverdiere J., Nabid A., de Bedoya L.D., et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol 2004, 171:1137-1140.
    • (2004) J Urol , vol.171 , pp. 1137-1140
    • Laverdiere, J.1    Nabid, A.2    de Bedoya, L.D.3
  • 4
    • 79955470908 scopus 로고    scopus 로고
    • Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10 year data from the TROG 96.01 randomised trial
    • Denham J.W., Steigler A., Lamb D.S., et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10 year data from the TROG 96.01 randomised trial. Lancet Oncol 2011, 12:451-459.
    • (2011) Lancet Oncol , vol.12 , pp. 451-459
    • Denham, J.W.1    Steigler, A.2    Lamb, D.S.3
  • 5
    • 0035869725 scopus 로고    scopus 로고
    • Updated results of the phase III radiation therapy oncology group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate
    • Lawton C.A., Winter K., Murray K., et al. Updated results of the phase III radiation therapy oncology group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001, 49(4):937-946.
    • (2001) Int J Radiat Oncol Biol Phys , vol.49 , Issue.4 , pp. 937-946
    • Lawton, C.A.1    Winter, K.2    Murray, K.3
  • 6
    • 0037072063 scopus 로고    scopus 로고
    • Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
    • Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360:103-108.
    • (2002) Lancet , vol.360 , pp. 103-108
    • Bolla, M.1    Collette, L.2    Blank, L.3
  • 7
    • 78049527402 scopus 로고    scopus 로고
    • External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
    • Bolla M., van Tienhoven G., Warde P., et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010, 11:1066-1073.
    • (2010) Lancet Oncol , vol.11 , pp. 1066-1073
    • Bolla, M.1    van Tienhoven, G.2    Warde, P.3
  • 8
    • 58649103315 scopus 로고    scopus 로고
    • Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial
    • Widmark A., Klepp O., Solberg A., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009, 373:301-308.
    • (2009) Lancet , vol.373 , pp. 301-308
    • Widmark, A.1    Klepp, O.2    Solberg, A.3
  • 9
    • 83955165856 scopus 로고    scopus 로고
    • Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial
    • Warde P., Mason M., Ding K., et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011, 378:2104-2111.
    • (2011) Lancet , vol.378 , pp. 2104-2111
    • Warde, P.1    Mason, M.2    Ding, K.3
  • 10
    • 0037674063 scopus 로고    scopus 로고
    • Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: radiation therapy oncology group 9413
    • Roach M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: radiation therapy oncology group 9413. J Clin Oncol 2003, 21(10):1904-1911.
    • (2003) J Clin Oncol , vol.21 , Issue.10 , pp. 1904-1911
    • Roach, M.1    DeSilvio, M.2    Lawton, C.3
  • 11
    • 34548682063 scopus 로고    scopus 로고
    • An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions
    • Lawton C.A., DeSilvio M., Roach M., et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007, 69(3):646-655.
    • (2007) Int J Radiat Oncol Biol Phys , vol.69 , Issue.3 , pp. 646-655
    • Lawton, C.A.1    DeSilvio, M.2    Roach, M.3
  • 12
    • 10644259702 scopus 로고    scopus 로고
    • The effectiveness of combining hormone therapy and radiotherapy in the treatment of prostate cancer
    • Jani A.B. The effectiveness of combining hormone therapy and radiotherapy in the treatment of prostate cancer. Expert Opin Pharmacother 2004, 5(12):2469-2477.
    • (2004) Expert Opin Pharmacother , vol.5 , Issue.12 , pp. 2469-2477
    • Jani, A.B.1
  • 13
    • 0344844488 scopus 로고    scopus 로고
    • Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number needed-to-treat analysis
    • Jani A.B., Kao J., Hellman S. Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number needed-to-treat analysis. Cancer 2003, 98(11):2351-2361.
    • (2003) Cancer , vol.98 , Issue.11 , pp. 2351-2361
    • Jani, A.B.1    Kao, J.2    Hellman, S.3
  • 14
    • 31044434562 scopus 로고    scopus 로고
    • Impact of hormone therapy on acute radiotherapy toxicity in the treatment of prostate cancer
    • Jani A.B., Gratzle J., Myers M. Impact of hormone therapy on acute radiotherapy toxicity in the treatment of prostate cancer. Prostate Cancer Prostatic Dis 2005, 8(3):224-228.
    • (2005) Prostate Cancer Prostatic Dis , vol.8 , Issue.3 , pp. 224-228
    • Jani, A.B.1    Gratzle, J.2    Myers, M.3
  • 15
    • 0642311912 scopus 로고    scopus 로고
    • Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the radiation therapy oncology group protocol 92-02
    • Hanks G.E., Pajak T.E., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the radiation therapy oncology group protocol 92-02. J Clin Oncol 2003, 21(21):3872-3978.
    • (2003) J Clin Oncol , vol.21 , Issue.21 , pp. 3872-3978
    • Hanks, G.E.1    Pajak, T.E.2    Porter, A.3
  • 16
    • 67149125847 scopus 로고    scopus 로고
    • Duration of androgen suppression in the treatment of prostate cancer
    • Bolla M., de Reijke T.M., van Tienhoven G., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360:2516-2527.
    • (2009) N Engl J Med , vol.360 , pp. 2516-2527
    • Bolla, M.1    de Reijke, T.M.2    van Tienhoven, G.3
  • 17
    • 84921803278 scopus 로고    scopus 로고
    • High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: results of a phase III randomized study
    • abstract #3
    • Nabid A, et al. High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: results of a phase III randomized study. Proceedings of the ASCO/ASTRO/SUO Genitourinary Cancers Symposium; 2013 abstract #3: p91.
    • (2013) Proceedings of the ASCO/ASTRO/SUO Genitourinary Cancers Symposium , pp. 91
    • Nabid, A.1
  • 18
    • 84888337623 scopus 로고    scopus 로고
    • Sequencing of agents for castration-resistant prostate cancer
    • Hurwitz M., Petrylak D.P. Sequencing of agents for castration-resistant prostate cancer. Oncology 2013, 27(11):1144-1158.
    • (2013) Oncology , vol.27 , Issue.11 , pp. 1144-1158
    • Hurwitz, M.1    Petrylak, D.P.2
  • 19
    • 84921825921 scopus 로고    scopus 로고
    • Phase III trial of dose escalated radiation therapy and standard androgen deprivation therapy (ADT) with a GnRH agonist vs. dose escalated radiation therapy and enhanced ADT with a GnRH agonist and TAK-700 for men with high risk prostate cancer
    • Accessed 21.07.14.
    • Radiation Therapy Oncology Group trial 1115. Phase III trial of dose escalated radiation therapy and standard androgen deprivation therapy (ADT) with a GnRH agonist vs. dose escalated radiation therapy and enhanced ADT with a GnRH agonist and TAK-700 for men with high risk prostate cancer. ; Accessed 21.07.14. http://www.rtog.org.
  • 20
    • 84921794605 scopus 로고    scopus 로고
    • Androgen deprivation therapy and high dose radiotherapy with or without whole-pelvic radiotherapy in unfavorable intermediate or favorable high-risk prostate cancer: a phase III randomized trial.
    • Accessed 21.07.14.
    • Radiation Therapy Oncology Group trial 0924. Androgen deprivation therapy and high dose radiotherapy with or without whole-pelvic radiotherapy in unfavorable intermediate or favorable high-risk prostate cancer: a phase III randomized trial. ; Accessed 21.07.14. http://www.rtog.org.
  • 21
    • 79960227242 scopus 로고    scopus 로고
    • Radiotherapy and short-term androgen deprivation for localized prostate cancer
    • Jones C.U., Hunt D., McGowan D.G., et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011, 365:107-118.
    • (2011) N Engl J Med , vol.365 , pp. 107-118
    • Jones, C.U.1    Hunt, D.2    McGowan, D.G.3
  • 22
    • 13844253671 scopus 로고    scopus 로고
    • Hormone therapy adjuvant to external beam radiotherapy for early prostate cancer: a complication-adjusted number-needed to treat (NNT) analysis
    • Jani A.B., Kao J., Heimann R., Hellman S. Hormone therapy adjuvant to external beam radiotherapy for early prostate cancer: a complication-adjusted number-needed to treat (NNT) analysis. Int J Radiat Oncol Biol Phys 2005, 61(3):687-694.
    • (2005) Int J Radiat Oncol Biol Phys , vol.61 , Issue.3 , pp. 687-694
    • Jani, A.B.1    Kao, J.2    Heimann, R.3    Hellman, S.4
  • 23
    • 84863629926 scopus 로고    scopus 로고
    • High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes
    • Edelman S., Liauw S.L., Rossi P.J., Cooper S., Jani A.B. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes. Int J Radiat Oncol Biol Phys 2012, 83(5):1473-1479.
    • (2012) Int J Radiat Oncol Biol Phys , vol.83 , Issue.5 , pp. 1473-1479
    • Edelman, S.1    Liauw, S.L.2    Rossi, P.J.3    Cooper, S.4    Jani, A.B.5
  • 24
    • 84921767469 scopus 로고    scopus 로고
    • A phase III prospective randomized trial of dose-escalated radiotherapy with or without short-term androgen-deprivation therapy for patients with intermediate-risk prostate cancer.
    • Accessed 21.07.14.
    • Radiation Therapy Oncology Group trial 0815. A phase III prospective randomized trial of dose-escalated radiotherapy with or without short-term androgen-deprivation therapy for patients with intermediate-risk prostate cancer. ; Accessed 21.07.14. http://www.rtog.org.
  • 25
    • 0034644401 scopus 로고    scopus 로고
    • Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer
    • D'Amico A.V., Schultz D., Loffredo M., et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. J Am Med Assoc 2000, 284:1280-1283.
    • (2000) J Am Med Assoc , vol.284 , pp. 1280-1283
    • D'Amico, A.V.1    Schultz, D.2    Loffredo, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.